Develop and market plasma-derived protein therapeutics. Offer treatments for rabies, cytomegalovirus, and alpha-1 antitrypsin deficiency. Now — the numbers.
This is an established company with proven profits.
Average growth of 15% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $63.9M would still be left in the vault — a solid cushion for hard times.
The market pays 22.6× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 78% of them.
Analysts' average target sits 89% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
The stock trades below its recent peak — about 15% off the top. A pullback, not a collapse.
Over the last 4 years, sales grew about 15% a year on average.
There is $75.5M in the vault; even if every debt were paid off, $63.9M would remain.
It pays out $0.42 per share each year — regular cash for whoever holds the stock.
The growth engine is running at low revs right now. Report-card grade: 47/100.
On our five-subject report card, KMDA sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: KMDA is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.